Current Clinical Trials
Multiple clinical trials are ongoing in the Optical Molecular Imaging Group. The overview below shows which trials are currently running and their status.
IMI-OPTIC – Anne van der Waaij and Sara Hone-Lopez
The IMI-OPTIC Study: Quantitative fluorescence molecular endoscopy using durvalumab-680LT to gain insight into the heterogeneity of programmed death-1 ligand (PD-L1) expression before and after neoadjuvant treatment in esophageal cancer.
Started February 2023, currently enrolling patients.
LEAF – Iris Schmidt & Pia Volkmer
Targeted fluorescence imaging using bevacizumab-800CW within neovascular Age-related Macular Degeneration (AMD) patients to evaluate the upregulation of VEGF.
Started October 2022, currently enrolling patients
SENSITIVE – Jouke van der Laan
An integrated approach of Raman spectroscopy and scattering measurements during endoscopy for real-time in vivo detection of field cancerization in the alimentary tract.
Started July 2022, currently enrolling patients.
SELECT – Femke van der Zant and Eline Feitsma
Detection of tumor tissue in peritoneal metastases of colorectal origin using Bevacizumab-IRDye800CW during diagnostic laparoscopy
Started May 2022, currently enrolling patients.
GLANS – Thom Nijboer
Visualization and resection margin assessment of penile carcinoma using the fluorescent tracer cetuximab-800CW and Surgvision camera system.
Started March 2022, currently enrolling patients.
TARGET-Beva – Eline Feitsma
Margin and metastatic lymph node detection in patients with thyroid carcinoma, utilizing the fluorescent tracer Bevacizumab-IRDye800CW and the Quest Platform Camera system for in vivo imaging.
Started December 2021, currently enrolling patients.
DEFENCE – Sara Hone-Lopez and Andrea Sterkenburg
Studying the gut immune system and its changes during immunotherapy to understand the determinants of immunotherapy response.
Started November 2021, currently enrolling patients.
LUMINA – Bianca Dijkstra
Evaluating the feasibility of applying bevacizumab-IRDye800CW for molecular fluorescence guided surgery in meningioma patients.
Started November 2021, currently enrolling patients.
DEPARTURE – Iris Schmidt
The DEPARTURE study evaluates the feasibility of using intraoperative fluorescence imaging for the detection of bevacizumab-800CW accumulation in pituitary neuroendocrine tumor tissue.
Started November 2020. Last patient in October 2022.
Utilizing Indocyanine Green (ICG) during total thyroidectomy for the purpose of parathyroid gland identification and preservation by means of fluorescence-guided surgery.
Started November 2020. Last patient in September 2022.
TRACT-II – Anne van der Waaij and Wouter Hooghiemstra
Visualization of treatment response using cetuximab-800CW during fluorescence endoscopy in rectal cancer.
Started November 2020. Last patient in January 2022.
VISION – Ruben Gabriëls and Anne van der Waaij
Phase I feasibility study investigating vedoluzimab distribution and detection vedoluzimab target cells in patient with inflammatory bowel disease.
Started January 2020. Last patient in April 2022.
ESCEND – Ruben Gabriëls and Wouter Hooghiemstra
Phase II near-infrared fluorescent endoscopy in combination with Bevacuzimab-IRDye800CW to visualize HD white light invisible dysplastic esophageal lesions.
Started July 2019. Last patient in April 2022.
ORCA – Iris Schmidt and Anne van der Waaij
Fluorescence molecular endoscopy for response monitoring of esophageal cancer patients after neoadjuvant chemoradiotherapy using bevacizumab-800CW.
Started November 2018. Last patient in September 2022.
COUGAR – Jouke van der Laan and Boudewijn de Vries
Perihilar cholangiocarcinoma detection using an intraoperative and endoscopic fluorescence guided approach using Bevacizumab-800CW.
Started July 2018. Currently enrolling patients.
